{"id":70765,"date":"2026-05-12T10:53:49","date_gmt":"2026-05-12T10:53:49","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&p=70765"},"modified":"2026-05-21T07:14:09","modified_gmt":"2026-05-21T07:14:09","slug":"cagrisema","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nl\/cagrisema\/","title":{"rendered":"CagriSema Blend (Cagrilintide 5 mg + Semaglutide 5 mg)"},"content":{"rendered":"

<\/p>\n

\n

Quick Answer \u2014 What is CagriSema?<\/h3>\n

CagriSema<\/strong> is the co-formulated combination of cagrilintide<\/a> (long-acting amylin analog) and semaglutide<\/a> (long-acting GLP-1 agonist) in a single lyophilized vial. It is the lead Phase 3 obesity programme from Novo Nordisk and produced body-weight reductions of approximately 20\u201323% over 68 weeks in the REDEFINE-1 trial \u2014 effect sizes comparable to triple-agonist retatrutide<\/a> achieved through the combination of two single-receptor agonists rather than a single multi-agonist molecule. Each vial contains 5\u00a0mg cagrilintide + 5\u00a0mg semaglutide for laboratory research use only.<\/p>\n<\/div>\n

Wat u krijgt bij MedsBase:<\/strong> Research-grade lyophilized peptide blend \u00b7 HPLC \u226599% purity (each component, COA on request) \u00b7 Discreet temperature-stable packaging \u00b7 Worldwide peptide courier \u00b7 1,400+ verified klantbeoordelingen<\/a><\/div>\n

\ud83d\udce6 Elke bestelling is gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Specificatie<\/th>\nDetail<\/th>\n<\/tr>\n<\/thead>\n
Composition<\/strong><\/td>\nCagrilintide 5\u00a0mg + Semaglutide 5\u00a0mg per vial (1:1 mass ratio, co-formulated)<\/td>\n<\/tr>\n
Total Peptide per Vial<\/strong><\/td>\n10\u00a0mg total peptide mass (5\u00a0mg + 5\u00a0mg)<\/td>\n<\/tr>\n
Component CAS Numbers<\/strong><\/td>\n1415456-99-3 (cagrilintide) \/ 910463-68-2 (semaglutide)<\/td>\n<\/tr>\n
Receptor Profile<\/strong><\/td>\nAmylin \/ calcitonin receptor family (AMY1\/2\/3) plus<\/em> GLP-1 receptor \u2014 mechanistically complementary, non-overlapping<\/td>\n<\/tr>\n
Form<\/strong><\/td>\nLyophilized co-formulated powder (white to off-white)<\/td>\n<\/tr>\n
Zuiverheid<\/strong><\/td>\n\u226599% (each component HPLC verified, COA on request)<\/td>\n<\/tr>\n
Half-life (per component)<\/strong><\/td>\nCagrilintide ~159 hours; Semaglutide ~165 hours \u2014 both supporting once-weekly subcutaneous dosing<\/td>\n<\/tr>\n
Opslag<\/strong><\/td>\nLyofiliseerd: 2\u20138 \u00b0C (koelkast) voor werkvoorraad; \u221220 \u00b0C voor langdurige opslag van ongeopende flesjes. Gereconstitueerd: 2\u20138 \u00b0C, gebruik binnen ~30 dagen. Bescherm tegen licht. Vries de gereconstitueerde oplossing niet in en ontdooi deze niet.<\/td>\n<\/tr>\n
Oplosbaarheid<\/strong><\/td>\nBacteriostatic water (recommended). Both peptides reconstitute simultaneously from the same vial.<\/td>\n<\/tr>\n
Onderzoeksgebruik<\/strong><\/td>\nAlleen voor laboratoriumonderzoek. Niet voor humaan of veterinair diagnostisch of therapeutisch gebruik.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

What Is CagriSema?<\/h2>\n

CagriSema<\/strong> is Novo Nordisk’s developmental name for the fixed-ratio combination of two long-acting peptides in a single subcutaneous formulation: cagrilintide<\/a> (the long-acting amylin analog, developmental code AM833) and semaglutide<\/a> (the long-acting GLP-1 receptor agonist marketed as Ozempic and Wegovy as a stand-alone agent). The combination is the lead Phase 3 obesity programme in Novo Nordisk’s pipeline and reported the REDEFINE-1 trial results in 2024\u20132025: approximately 20\u201323% body-weight reduction over 68 weeks at the 2.4\u00a0mg + 2.4\u00a0mg weekly dose \u2014 effect sizes that place CagriSema in the same range as the triple-receptor-agonist retatrutide<\/a> while taking a completely different pharmacological route.<\/p>\n

The strategic rationale for CagriSema rests on the complementary, non-overlapping mechanisms<\/strong> of its two component peptides. GLP-1 receptor agonists (semaglutide) act predominantly on hypothalamic arcuate-nucleus POMC neurons (central appetite regulation) and pancreatic beta-cells (glucose-dependent insulin secretion). Amylin\/calcitonin receptor agonists (cagrilintide) act predominantly on brainstem area-postrema neurons (per-meal satiety reinforcement) and pancreatic alpha-cells (glucagon suppression). The two mechanisms are mechanistically additive rather than redundant, which is why the combination produces body-weight effects substantially greater than either component alone \u2014 demonstrated in the Phase 2 head-to-head data where CagriSema outperformed both cagrilintide monotherapy and semaglutide monotherapy.<\/p>\n

This research-grade CagriSema co-formulation contains 5\u00a0mg cagrilintide + 5\u00a0mg semaglutide per vial<\/strong> in a 1:1 mass ratio matching the fixed-dose ratio used in the Phase 3 clinical programme. Both components are pre-mixed in the same lyophilized vial; reconstitution with bacteriostatic water yields a working solution containing both peptides simultaneously. This approach eliminates the need to combine separate vials at the bench. CagriSema is niet goedgekeurd<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use as of current literature; regulatory submission and review are ongoing. The research-grade CagriSema sold here is supplied uitsluitend voor laboratoriumonderzoek<\/strong> and is not intended for human or veterinary administration. For deeper detail on each component, see our individual Cagrilintide<\/a> en Semaglutide<\/a> productpagina's.<\/p>\n

Mechanism of Action \u2014 Complementary Dual-Receptor Pharmacology<\/h2>\n

What makes CagriSema mechanistically distinctive among current metabolic-research compounds is that the two component peptides activate entirely different receptor families with non-overlapping central and peripheral mechanisms<\/strong> \u2014 achieving multi-axis pharmacology through combination rather than through engineering a single multi-agonist molecule like tirzepatide or retatrutide:<\/p>\n